TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of TORRENT PHARMACEUTICALS have increased by 21.39% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 13.19 % YoY. |
||
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹13,980 Cr | ₹11,516 Cr | ₹10,728 Cr | ₹9,620 Cr | ₹8,508 Cr |
| Expenses | ₹9,607 Cr | ₹7,812 Cr | ₹7,364 Cr | ₹6,796 Cr | ₹6,077 Cr |
| Operating Profit (Excl OI) | ₹4,373 Cr | ₹3,704 Cr | ₹3,364 Cr | ₹2,824 Cr | ₹2,431 Cr |
| Other Income | ₹92 Cr | ₹40 Cr | ₹62 Cr | ₹63 Cr | ₹197 Cr |
| Interest | ₹385 Cr | ₹252 Cr | ₹354 Cr | ₹333 Cr | ₹255 Cr |
| Depreciation | ₹1,119 Cr | ₹795 Cr | ₹808 Cr | ₹707 Cr | ₹662 Cr |
| Profit Before Tax | ₹2,872 Cr | ₹2,673 Cr | ₹2,352 Cr | ₹1,847 Cr | ₹1,226 Cr |
| Profit After Tax | ₹2,138 Cr | ₹1,911 Cr | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr |
| Consolidated Net Profit | ₹2,163 Cr | ₹1,911 Cr | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr |
| Earnings Per Share (Rs) | ₹63.92 | ₹56.47 | ₹48.94 | ₹36.79 | ₹45.92 |
| PAT Margin (%) | 10.86 | 11.34 | 9.92 | 7.63 | 5.11 |
| ROE(%) | 26.76 | 26.46 | 25.38 | 20.50 | 13.18 |
| ROCE(%) | 19.27 | 27.32 | 24.28 | 20.32 | 14.35 |
| Total Debt/Equity(x) | 1.76 | 0.40 | 0.57 | 0.85 | 0.68 |
Key Financials |
||
| Market Cap | : | ₹ 180,347.6 Cr |
| Revenue (TTM) | : | ₹ 17,400.0 Cr |
| Net Profit(TTM) | : | ₹ 2,099.0 Cr |
| EPS (TTM) | : | ₹ 55.2 |
| P/E (TTM) | : | 85.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TORRENT PHARMACEUTICALS | 3.4% | 0.7% | 32.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 5.2% | 4.3% | 8% |
| DIVIS LABORATORIES | 3.6% | 7.6% | 50.5% |
| CIPLA | 2% | 6% | -6.7% |
| DR REDDYS LABORATORIES | 2.3% | 14% | 13.6% |
| MANKIND PHARMA | 2.7% | 1.8% | 5.6% |
| LUPIN | -0.3% | -0.9% | 1.2% |
| ZYDUS LIFESCIENCES | -3.6% | 3.6% | 22.8% |
| AUROBINDO PHARMA | 6.7% | 6.7% | 57.1% |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 21.39 % |
| 5 Yr CAGR | 13.22 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹13,980 Cr | 21.39 | |
| Mar2025 | ₹11,516 Cr | 7.35 | |
| Mar2024 | ₹10,728 Cr | 11.51 | |
| Mar2023 | ₹9,620 Cr | 13.07 | |
| Mar2022 | ₹8,508 Cr | - | |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 18.05 % |
| 5 Yr CAGR | 15.81 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,373 Cr | 18.05 | |
| Mar2025 | ₹3,704 Cr | 10.13 | |
| Mar2024 | ₹3,364 Cr | 19.11 | |
| Mar2023 | ₹2,824 Cr | 16.15 | |
| Mar2022 | ₹2,431 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -2.77 % |
| 5 Yr CAGR | 2.28 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 31.28% | -2.77 | |
| Mar2025 | 32.17% | 2.62 | |
| Mar2024 | 31.35% | 6.81 | |
| Mar2023 | 29.35% | 2.69 | |
| Mar2022 | 28.58% | - | |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 13.19 % |
| 5 Yr CAGR | 29.17 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,163 Cr | 13.19 | |
| Mar2025 | ₹1,911 Cr | 15.39 | |
| Mar2024 | ₹1,656 Cr | 33.02 | |
| Mar2023 | ₹1,245 Cr | 60.22 | |
| Mar2022 | ₹777 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -4.23 % |
| 5 Yr CAGR | 20.74 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.86 % | -4.23 | |
| Mar2025 | 11.34 % | 14.31 | |
| Mar2024 | 9.92 % | 30.01 | |
| Mar2023 | 7.63 % | 49.32 | |
| Mar2022 | 5.11 % | - | |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 13.19 % |
| 5 Yr CAGR | 8.62 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹64 | 13.19 | |
| Mar2025 | ₹56 | 15.39 | |
| Mar2024 | ₹49 | 33.03 | |
| Mar2023 | ₹37 | -19.88 | |
| Mar2022 | ₹46 | - | |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | -29.47 % |
| 5 Yr CAGR | 7.65 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 19.27% | -29.47 | |
| Mar2025 | 27.32% | 12.52 | |
| Mar2024 | 24.28% | 19.49 | |
| Mar2023 | 20.32% | 41.60 | |
| Mar2022 | 14.35% | - | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹4,741.0 |
| Current MarketCap | : | ₹ 180,347.6 Cr |
| Updated EOD on | : | Nov 06,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | 3.4% |
0.7% |
32.6% |
| SENSEX | 8.8% |
10.9% |
-4% |
TORRENT PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 100 LARGECAP TMC INDEX | 8.1% | 8.7% | -2.2% |
| BSE INDIA 150 INDEX | 7.7% | 7.7% | -1.5% |
| BSE 200 | 7.6% | 7.1% | -2.2% |
| BSE 250 LARGEMIDCAP INDEX | 7.5% | 6.8% | -2% |
| BSE 500 | 7.2% | 5.7% | -1.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY100 ESG SECTOR LEADERS | 9.1% | 9.4% | -3.5% |
| NIFTY 100 | 8.1% | 8.5% | -2.3% |
| NIFTY INDIA CONSUMPTION | 7.8% | 8% | -4.4% |
| NIFTY 200 | 7.6% | 7.1% | -1.7% |
| NIFTY100 ESG | 7.6% | 8.8% | 0.3% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 21.39% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 13.19 % YoY .
Check out Intrinsic Value of Peers of TORRENT PHARMACEUTICALS
Compare Stock Analytics of Peers of TORRENT PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
